Compare Cytokinetics Inc (CYTK) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Cytokinetics Inc trades at $82.73 (market cap $11.12B), while JPMorgan Diversified Return International Eqty ETF trades at $73.33. The key difference: Cytokinetics Inc is trading nearer its 52-week high, JPMorgan Diversified Return International Eqty ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | JPIN | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | — |
52-Week High | $87.26 | $76.96 |
52-Week Low | $33.23 | $63.14 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
JPIN trades at $72.785, down 0.78% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance near $73 and support at $72. Recent corporate actions include a declared dividend of $0.91 scheduled for June 2026. Market sentiment remains mixed, with oscillators neutral and moving averages signaling bearish pressure.
The outlook for JPIN is cautious due to weak technical momentum and limited fundamental data availability. Key risks include market volatility and reliance on international equity performance. Investors should monitor upcoming financial disclosures for clarity on valuation and profitability metrics to assess long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
